IIRC, Abgenix intentionally pick an Fc type in their mice that would not be able to instigate ADCC. I believe they were concerned it might lead to unpredictable (potentially unwanted) immune system related side effects. ADCC is presumably a good thing in fighting cancer where the goal is to destroy the cancer cell. However, there may be indications where you merely want to modulate receptor activity rather than destroy a cell. AMGN dumped most of Abgenix's research programs, so it's an academic question.
I forget what Fc type(s) MEDX chose. Do you recall if they picked more than one? Are all the antibodies the MEDX mice produce capable of inducing ADCC?
What do you think of MEDX in general? Someone asked me about it the other day and I haven't looked at them in a while.
Neblo discussed the ADCC issue on the Yahoo IMCL mb many years ago.
Market Data 
Markets 
AI
